CHRS +30% on what seems like an overreaction to info from last night's 4Q17 CC.
On the CC, management said that the FDA accepted CHRS' proposed assay to measure immunogenicity of the company's Neulasta FoB, which is its lead program.
However, FDA acceptance of the proposed assay is not the same as FDA acceptance of the assayed immunogenicity data, which is currently the issue of consequence for this program.
Market Data 
Markets 
AI
